CSAClinical-Stage Asset Intelligence
Catalyst calendar Get the data
Home / Jazz Pharmaceuticals PLC (JAZZ) / zanidatamab
Forward catalyst · JAZZ

zanidatamab

Sponsor Jazz Pharmaceuticals PLC · listed as JAZZ

READOUT Phase 3 Confidence: medium Source: clinicaltrials

zanidatamab is a clinical-stage drug asset sponsored by Jazz Pharmaceuticals PLC, listed as JAZZ. CSA tracks 2 forward catalysts for it — the nearest is a readout expected Jul 31, 2026 (day precision, medium confidence), tied to trial NCT05152147. The asset is in Phase 3 and currently active not recruiting, studied in Gastric Neoplasms. It appears across 4 tracked trials in the CSA sample.

Next catalyst

Event typeREADOUT
Expected date2026-07-31
As disclosedJul 31, 2026
Date precisionday
Confidencemedium
Verify at source →

Trial & sponsor

Trial (NCT)NCT05152147
PhasePHASE3
StatusACTIVE_NOT_RECRUITING
Lead sponsorJazz Pharmaceuticals
Listed asJAZZ
Condition(s)Gastric Neoplasms; Gastroesophageal Adenocarcinoma; Esophageal Adenocarcinoma

All tracked catalysts for zanidatamab

DateEventConfidenceTrial
2026-07-31READOUTmediumNCT05152147
2027-06-30READOUTmediumNCT05615818
!

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.

Get the full dataset — $499 →   More JAZZ catalysts